CD1D and acute lymphoblastic leukemia: Despite the small size of the CD1d-Vδ2 bsTCE, which is below the renal threshold for first-pass clearance,25 antitumor activity was still evident using an administration frequency of only once every 2 weeks in a s.c. T-ALL/PBMC model.